BioLineRX
BLRX
10 hedge funds and large institutions have $5.12M invested in BioLineRX in 2013 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
31% more capital invested
Capital invested by funds: $3.91M → $5.12M (+$1.21M)
11% more funds holding
Funds holding: 9 → 10 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$158K |
| 2 |
SM
Senvest Management
New York
|
+$131K |
| 3 |
Renaissance Technologies
New York
|
+$62.6K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.54K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$501K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$25K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
O
1
OrbiMed
New York
| $2.92M | -$501K | -424 | -16% |
|
|
SM
2
Senvest Management
New York
| $1.51M | +$131K | +111 | +11% |
|
|
3
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $446K | +$158K | +134 | +65% |
|
|
4
Renaissance Technologies
New York
| $135K | +$62.6K | +53 | +106% |
|
5
Bank of New York Mellon
New York
| $39K | – | – | – |
|
6
Royal Bank of Canada
Toronto,
Ontario, Canada
| $27K | – | – | – |
|
|
VKH
7
Virtu KCG Holdings
New York
| $24K | +$21.3K | +18 | New |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $4K | +$3.54K | +3 | New |
|
9
Wells Fargo
San Francisco,
California
| $2K | – | – | – |
|
10
Citigroup
New York
| $1K | – | – | – |
|
|
CS
11
Credit Suisse
Zurich,
Switzerland
| – | -$25K | -26 | Closed |
|
BLRX Hedge Fund Activity: Q3 2013 in Review
10 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q3 2013, worth a combined $5.12M — up 31% from $3.91M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BLRX positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Deutsche Bank, adding an estimated $158K. The largest seller was OrbiMed, cutting an estimated $501K.
- 10 institutional investors held BioLineRX (BLRX) as of Q3 2013, up from 9 in Q2 2013.
- Funds reported $5.12M of BioLineRX stock for Q3 2013, up 31% quarter-over-quarter.
- 2 funds opened new BioLineRX positions in Q3 2013 and 1 closed out, a net change of +1 holder.
- The largest BioLineRX buyer in Q3 2013 was Deutsche Bank, an estimated $158K added.
- The largest BioLineRX seller in Q3 2013 was OrbiMed, an estimated $501K sold.
Based on aggregated 13F filings for Q3 2013.